Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 5/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8099706 | 0.94 | ALDH1A1 (0.36) | POLBALDH1A1SMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL4632603 | 0.77 | ALDH1A1 (0.38) | POLBALDH1A1TDP1L3MBTL1KDM4E | |
| SCHEMBL2154609 | 0.76 | ALDH1A1 (0.39) | ALDH1A1TSHR | |
| SCHEMBL13948532 | 0.76 | TDP1 (0.46) | POLBALDH1A1SMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL12348427 | 0.75 | SMN1; SMN2 (0.39) | POLBALDH1A1SMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL27344248 | 0.74 | ALDH1A1 (0.33) | POLBALDH1A1SMN1; SMN2TDP1TSHR | |
| SCHEMBL10564352 | 0.74 | POLB (0.58) | POLBALDH1A1SMN1; SMN2TDP1KDM4E | |
| SCHEMBL21224555 | 0.74 | TDP1 (0.44) | POLBALDH1A1SMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL816707 | 0.74 | ALDH1A1 (0.38) | ALDH1A1KDM4ETSHR | |
| SCHEMBL6512240 | 0.74 | TDP1 (0.48) | ALDH1A1SMN1; SMN2TDP1IMPDH2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172401-A1 | BENZIMIDAZOLE DERIVATIVE AND USE AS ANGIOTENSIN II ANTAGONIST | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-07-05 | — | — | US | disclosed |
| EP-2119715-B1 | Benzimidazole derivative and its use as AII receptor antagonist | TAKEDA PHARMACEUTICAL (JP) | 2012-05-30 | — | — | EP | disclosed |
| US-7875637-B2 | improving insulin resistance with azilsartan medoxomil, aka (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate; combination therapy with other antidiabetic agents | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-25 | — | — | US | disclosed |
| EP-1863801-B1 | BENZIMIDAZOLE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2010-09-29 | — | — | EP | disclosed |
| EP-2119715-A1 | Benzimidazole derivative and its use as aii receptor antagonist | Takeda Pharmaceutical Company Limited (JP) | 2009-11-18 | — | — | EP | disclosed |
| US-20090270464-A1 | Benzimidazole derivative and use as a II receptor antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-10-29 | — | — | US | disclosed |
| EP-1857457-B1 | Benzimidazole derivative and its use as AII receptor antagonist | TAKEDA PHARMACEUTICAL (JP) | 2009-08-19 | — | — | EP | disclosed |
| US-7572920-B2 | Benzimidazole derivative and use as a II receptor antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-11 | — | — | US | disclosed |
| US-20090054502-A1 | Benzimidazole Derivative and Use as Angiotensin II Antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-02-26 | — | — | US | disclosed |
| EP-1863801-A2 | BENZIMIDAZOLE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
| EP-1857457-A2 | Benzimidazole derivative and its use as AII receptor antagonist | Takeda Pharmaceutical Company Limited (JP) | 2007-11-21 | — | — | EP | disclosed |
| EP-1718641-B1 | BENZIMIDAZOLE DERIVATIVE AND ITS USE AS A II RECEPTOR ANTAGONIST | TAKEDA PHARMACEUTICAL (JP) | 2007-08-15 | — | — | EP | disclosed |
| US-7157584-B2 | Benzimidazole derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-02 | — | — | US | disclosed |
| US-20060281795-A1 | Benzinidazole Derivative and Use As AII Receptor Antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-12-14 | — | — | US | disclosed |
| WO-2005080384-A9 | BENZIMIDAZOLE DERIVATIVE AND USE AS AII RECEPTOR ANTAGONIST | TAKEDA PHARMACEUTICAL (JP) | 2006-11-30 | — | — | WO | disclosed |
| EP-1718641-A2 | BENZIMIDAZOLE DERIVATIVE AND ITS USE AS AII RECEPTOR ANTAGONIST | Takeda Pharmaceutical Company Limited (JP) | 2006-11-08 | — | — | EP | disclosed |
| WO-2006107062-A2 | BENZIMIDAZOLE DERIVATIVE AND USE AS ANGIOTENSIN II ANTAGONIST | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-12 | — | — | WO | disclosed |
| WO-2005080384-A2 | BENZIMIDAZOLE DERIVATIVE AND USE AS AII RECEPTOR ANTAGONIST | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-09-01 | — | — | WO | disclosed |
| US-20050187269-A1 | Benzimidazole derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172401-A1 | BENZIMIDAZOLE DERIVATIVE AND USE AS ANGIOTENSIN II ANTAGONIST | AGTR2, AGTR1, ACE | POLB 3193/4885ALDH1A1 221/4885SMN1; SMN2 4555/4885 |
| US-20090054502-A1 | Benzimidazole Derivative and Use as Angiotensin II Antagonist | AGTR2, AGTR1, ACE | POLB 3193/4885ALDH1A1 221/4885SMN1; SMN2 4555/4885 |
| US-20060281795-A1 | Benzinidazole Derivative and Use As AII Receptor Antagonist | AGTR1, AGTR2, GPR119 | POLB 4653/4885ALDH1A1 413/4885SMN1; SMN2 4529/4885 |
| US-20050187269-A1 | Benzimidazole derivative and use thereof | REN, H1-3, GPR119 | POLB 3655/4885ALDH1A1 314/4885SMN1; SMN2 4004/4885 |
| US-20090270464-A1 | Benzimidazole derivative and use as a II receptor antagonist | AGTR1, BDKRB1, GPR119 | POLB 4419/4885ALDH1A1 1044/4885SMN1; SMN2 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.